- $195.92m
- $186.76m
Annual balance sheet for Elicio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 88.8 | 50.5 | 12.9 | 17.6 | 18.6 |
| Net Total Receivables | 0.806 | 0 | 0.173 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 91.2 | 51.4 | 16.3 | 20.7 | 19.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.44 | 0.425 | 7.28 | 6.19 | 5.08 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 96.5 | 52.8 | 27.1 | 28.2 | 25.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.3 | 6.37 | 9.77 | 11.5 | 8.11 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15 | 9.02 | 15.8 | 39.5 | 24.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 81.5 | 43.8 | 11.4 | -11.3 | 1.64 |
| Total Liabilities & Shareholders' Equity | 96.5 | 52.8 | 27.1 | 28.2 | 25.9 |
| Total Common Shares Outstanding |